再鼎医药宣布Zocilurtatug Pelitecan(Zoci)获欧洲药品管理局孤儿药资格认定,用于治疗来源于肺的神经内分泌癌

美通社
Jun 16

欧洲药品管理局孤儿药品委员会认为,zoci的初步临床数据显示,其在复发或难治性广泛期小细胞肺癌中,相较现有获批疗法具有潜在临床相关优势 小细胞肺癌是最主要的来源于肺的神经内分泌癌,全球每年约有37.5万新发病例,目前治疗选择有限 欧洲药品管理局授予 zoci 用于治疗来源于肺的神经内分泌癌的孤儿药资格认定;此前不久,zoci已获得美国食品药品监督管理局针对肺外神经内分泌癌的快速通道资格认定,并在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10